Pharmerica (PMC) Misses Q3 EPS by 7c; Guides FY16 Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
PharMerica Reports Third Quarter 2016 Results
November 9, 2016 8:00 AM ESTExpects Strong Fourth Quarter 2016 Results
Preliminary 2017 Guidance Within Range of Analysts Average Expectations
Company Revises 2016 Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (the Corporation or the Company) (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter ended September 30, 2016.
       3Q16 Results ÂComparison to3Q15
ÂComparison to2Q16
Revenue   $512.6 million  Increase of 2.8%  Decrease of 1.3% Gross profit  ... More